Today: 19 May 2026
Browse Category

NYSE:TOST 20 October 2025 - 19 December 2025

Toast (TOST) Stock on December 4, 2025: Analyst Upgrades, AI Strategy and Earnings Shape a High‑Growth, High‑Valuation Story

Toast (TOST) Stock on December 4, 2025: Analyst Upgrades, AI Strategy and Earnings Shape a High‑Growth, High‑Valuation Story

Toast, Inc. traded at $35.17 per share with a market cap of $20.68 billion in early December 2025. JPMorgan upgraded the stock to Overweight with a $43 target on December 4, while UBS reiterated a Buy rating and $50 target the same day. BNP Paribas Exane raised its rating to Outperform with a $40 target on December 1. The stock’s valuation remains high, with a trailing P/E in the high-70s to low-80s.
4 December 2025
····
AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

The Nasdaq hit about 22,680 and the S&P 500 hovered near 6,664 as investors poured into AI-driven growth stocks. Nvidia surged nearly 60% year-over-year, while AMD almost doubled in 2025 after major AI chip deals. CrowdStrike traded near record highs, up 56% annually. Analysts remain bullish, but some warn valuations are stretched.
20 October 2025
·········

Stock Market Today

  • Yacktman Asset Management Cuts Alphabet Inc. Stake Amid Mixed Institutional Moves
    May 19, 2026, 2:13 PM EDT. Yacktman Asset Management LP reduced its stake in Alphabet Inc. (NASDAQ:GOOG) by 3.1% in Q4, selling 36,606 shares and holding 1,129,807 shares valued at $354.5 million, representing 5% of its portfolio. Other institutional investors showed varied activity with Brighton Jones LLC and Worldquant Millennium Advisors LLC increasing their holdings significantly. Alphabet's stock saw multiple analyst ratings, including 'outperform' and 'buy' with target prices ranging from $345 to $450, reflecting positive sentiment from firms like Scotiabank, TD Cowen, and Deutsche Bank. Institutional investors own 27.26% of Alphabet's shares. The stock remains a top focus amid ongoing trading by hedge funds and asset managers.

Latest articles

Why Recursion Stock Just Hit a 52-Week Low — and the FDA Update Traders Are Waiting For

Why Recursion Stock Just Hit a 52-Week Low — and the FDA Update Traders Are Waiting For

19 May 2026
New York, May 19, 2026, 2:04 PM EDT Recursion Pharmaceuticals shares fell in Tuesday afternoon trading after touching a fresh 52-week low, keeping pressure on one of the better-known AI drug-discovery names even as the company points to clinical progress and a cash runway into 2028. The stock was recently down about 2.2% at $2.825, after trading as low as $2.77, with volume above 10 million shares and a market value near $1.49 billion. Investing.com reported earlier Tuesday that Recursion had hit a 52-week low at $2.79 and said the shares were down about 36% over the past year. (Investing.com)
Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

19 May 2026
U.S. stocks fell Tuesday as the 10-year Treasury yield reached its highest point since January 2025, pressuring growth shares. Nvidia drew the most attention ahead of its earnings, with options markets pricing in a possible $355 billion swing in value. Dell highlighted new AI infrastructure partnerships, while ServiceNow received a fresh Buy rating from Bank of America.
Nvidia’s Earnings Could Make or Break the AI Stock Trade

Nvidia’s Earnings Could Make or Break the AI Stock Trade

19 May 2026
Nvidia rose 0.8% ahead of its earnings report, while CoreWeave dropped 3.7% after Google and Blackstone announced a $5 billion U.S. AI cloud venture using Google’s custom TPUs. The new venture will offer 500 megawatts of data-center capacity by 2027. AMD and Micron also gained, but Microsoft and Broadcom slipped. Investors are watching whether Nvidia can maintain dominance as competition in AI inference intensifies.
Go toTop